Edition:
United Kingdom

People: Atara Biotherapeutics Inc (ATRA.OQ)

ATRA.OQ on NASDAQ Stock Exchange Global Select Market

31.86USD
18 Apr 2019
Change (% chg)

-- (--)
Prev Close
$31.86
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
168,819
52-wk High
$54.45
52-wk Low
$27.85

Fust, Matthew 

Mr. Matthew K. Fust is an Independent Director of the Company. He has served as a member of the Board since March 2014. Mr. Fust has served on the board of directors of Dermira, Inc. since April 2014, MacroGenics, Inc. since March 2014, Sunesis Pharmaceuticals, Inc. since May 2005, and Ultragenyx Pharmaceutical, Inc. since January 2014. Mr. Fust was previously Executive Vice President and Chief Financial Officer of Onyx Pharmaceuticals, Inc., a biopharmaceutical company, from January 2009 through its acquisition by Amgen in October 2013. Mr. Fust continued as an employee of Amgen until January 2014. From May 2003 to December 2008, Mr. Fust served as Chief Financial Officer at Jazz Pharmaceuticals, Inc., a specialty pharmaceutical company. From 2002 to 2003, Mr. Fust served as Chief Financial Officer at Perlegen Sciences, a biopharmaceutical company. Previously, he was Senior Vice President and Chief Financial Officer at ALZA Corporation, a pharmaceutical company, where he was an executive from 1996 until 2002. From 1991 until 1996, Mr. Fust was a manager in the healthcare strategy practice at Andersen Consulting. Mr. Fust received a B.A. from the University of Minnesota and an M.B.A. from the Stanford Graduate School of Business.

Basic Compensation

Total Annual Compensation, USD 65,000
Restricted Stock Award, USD 96,150
Long-Term Incentive Plans, USD --
All Other, USD 176,789
Fiscal Year Total, USD 337,939

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --
Name Fiscal Year Total

Isaac Ciechanover

3,366,820

Utpal Koppikar

--

Joseph Newell

1,641,820

Christopher Haqq

3,298,020

Mitchall Clark

1,402,910

Gad Soffer

3,098,040
As Of  31 Dec 2017